TY - JOUR
T1 - Virologic and immunologic response to highly active antiretroviral therapy.
AU - Jacobson, Lisa P.
AU - Phair, John P.
AU - Yamashita, Traci E.
N1 - Funding Information:
This paper was an invited update of a previously reported review [32]. The authors would like to thank Joanne Mullen for her assistance in the review of the literature. Data in this manuscript were collected by MACS with centers (Principal Investigators) at The Johns Hopkins University Bloomberg School of Public Health (Lisa P. Jacobson, Joseph B. Mar-golick, and Alvaro Muñoz), Howard Brown Health Center and Northwestern University Medical School (John Phair), University of California, Los Angeles (Roger Detels and Beth Jamieson), and University of Pittsburgh (Charles Rinaldo). MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute. UO1-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, and UO1-AI-35041. Visit http://www.statepi.jhsph.edu/macs/macs.html for further information.
PY - 2004/6
Y1 - 2004/6
N2 - Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.
AB - Highly active antiretroviral therapy (HAART) delays clinical progression by suppressing viral replication, measured by a substantial reduction in HIV RNA, allowing the immune system to reconstitute, measured in most studies by an increase in CD4 cells. These virologic and immunologic consequences do not occur uniformly among HAART users. Markers of HIV disease stage at the time of HAART initiation are critical determinants of the progression while receiving HAART. In this report, we review studies describing the heterogeneous virologic and immunologic progression after the initiation of HAART, discuss methodologic concerns in the study of the response of biomarkers, and update findings obtained in the Multicenter AIDS Cohort Study, which show that CD4 cell count, history of antiretroviral therapy, and age at the time of initiation are independent determinants of response.
UR - http://www.scopus.com/inward/record.url?scp=24144482810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24144482810&partnerID=8YFLogxK
U2 - 10.1007/s11904-004-0011-1
DO - 10.1007/s11904-004-0011-1
M3 - Review article
C2 - 16091226
AN - SCOPUS:24144482810
SN - 1548-3568
VL - 1
SP - 74
EP - 81
JO - Current HIV/AIDS reports
JF - Current HIV/AIDS reports
IS - 2
ER -